1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
3.1. Market Snapshot
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
5.1. COVID-19 Landscape: Psoriasis Treatment Industry Impact
5.2. COVID 19 - Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
8.1. Psoriasis Treatment Market, by Drug Class
8.1.1. Interleukins
8.1.1.1. Market Revenue and Forecast
8.1.2. TNF Inhibitors
8.1.2.1. Market Revenue and Forecast
8.1.3. Others
8.1.3.1. Market Revenue and Forecast
9.1. Psoriasis Treatment Market, by Treatment Type
9.1.1. Biologic Drugs
9.1.1.1. Market Revenue and Forecast
9.1.2. Small Molecule Systemic Drugs
9.1.2.1. Market Revenue and Forecast
9.1.3. Tropical Therapies
9.1.3.1. Market Revenue and Forecast
10.1. Psoriasis Treatment Market, by Type
10.1.1. Psoriatic Arthritis
10.1.1.1. Market Revenue and Forecast
10.1.2. Plaque Psoriasis
10.1.2.1. Market Revenue and Forecast
10.1.3. Others
10.1.3.1. Market Revenue and Forecast
11.1. Psoriasis Treatment Market, by Route of Administration
11.1.1. Oral
11.1.1.1. Market Revenue and Forecast
11.1.2. Parenteral
11.1.2.1. Market Revenue and Forecast
11.1.3. Topical
11.1.3.1. Market Revenue and Forecast
12.1. Psoriasis Treatment Market, by Distribution Channel
12.1.1. Hospital Pharmacies
12.1.1.1. Market Revenue and Forecast
12.1.2. Online pharmacies
12.1.2.1. Market Revenue and Forecast
12.1.3. Retail Pharmacies
12.1.3.1. Market Revenue and Forecast
13.1. North America
13.1.1. Market Revenue and Forecast, by Drug Class
13.1.2. Market Revenue and Forecast, by Treatment Type
13.1.3. Market Revenue and Forecast, by Type
13.1.4. Market Revenue and Forecast, by Route of Administration
13.1.5. Market Revenue and Forecast, by Distribution Channel
13.1.6. U.S.
13.1.6.1. Market Revenue and Forecast, by Drug Class
13.1.6.2. Market Revenue and Forecast, by Treatment Type
13.1.6.3. Market Revenue and Forecast, by Type
13.1.6.4. Market Revenue and Forecast, by Route of Administration
13.1.6.5. Market Revenue and Forecast, by Distribution Channel
13.1.7. Rest of North America
13.1.7.1. Market Revenue and Forecast, by Drug Class
13.1.7.2. Market Revenue and Forecast, by Treatment Type
13.1.7.3. Market Revenue and Forecast, by Type
13.1.7.4. Market Revenue and Forecast, by Route of Administration
13.1.7.5. Market Revenue and Forecast, by Distribution Channel
13.2. Europe
13.2.1. Market Revenue and Forecast, by Drug Class
13.2.2. Market Revenue and Forecast, by Treatment Type
13.2.3. Market Revenue and Forecast, by Type
13.2.4. Market Revenue and Forecast, by Route of Administration
13.2.5. Market Revenue and Forecast, by Distribution Channel
13.2.6. UK
13.2.6.1. Market Revenue and Forecast, by Drug Class
13.2.6.2. Market Revenue and Forecast, by Treatment Type
13.2.6.3. Market Revenue and Forecast, by Type
13.2.6.4. Market Revenue and Forecast, by Route of Administration
13.2.6.5. Market Revenue and Forecast, by Distribution Channel
13.2.7. Germany
13.2.7.1. Market Revenue and Forecast, by Drug Class
13.2.7.2. Market Revenue and Forecast, by Treatment Type
13.2.7.3. Market Revenue and Forecast, by Type
13.2.7.4. Market Revenue and Forecast, by Route of Administration
13.2.7.5. Market Revenue and Forecast, by Distribution Channel
13.2.8. France
13.2.8.1. Market Revenue and Forecast, by Drug Class
13.2.8.2. Market Revenue and Forecast, by Treatment Type
13.2.8.3. Market Revenue and Forecast, by Type
13.2.8.4. Market Revenue and Forecast, by Route of Administration
13.2.8.5. Market Revenue and Forecast, by Distribution Channel
13.2.9. Rest of Europe
13.2.9.1. Market Revenue and Forecast, by Drug Class
13.2.9.2. Market Revenue and Forecast, by Treatment Type
13.2.9.3. Market Revenue and Forecast, by Type
13.2.9.4. Market Revenue and Forecast, by Route of Administration
13.2.9.5. Market Revenue and Forecast, by Distribution Channel
13.3. APAC
13.3.1. Market Revenue and Forecast, by Drug Class
13.3.2. Market Revenue and Forecast, by Treatment Type
13.3.3. Market Revenue and Forecast, by Type
13.3.4. Market Revenue and Forecast, by Route of Administration
13.3.5. Market Revenue and Forecast, by Distribution Channel
13.3.6. India
13.3.6.1. Market Revenue and Forecast, by Drug Class
13.3.6.2. Market Revenue and Forecast, by Treatment Type
13.3.6.3. Market Revenue and Forecast, by Type
13.3.6.4. Market Revenue and Forecast, by Route of Administration
13.3.6.5. Market Revenue and Forecast, by Distribution Channel
13.3.7. China
13.3.7.1. Market Revenue and Forecast, by Drug Class
13.3.7.2. Market Revenue and Forecast, by Treatment Type
13.3.7.3. Market Revenue and Forecast, by Type
13.3.7.4. Market Revenue and Forecast, by Route of Administration
13.3.7.5. Market Revenue and Forecast, by Distribution Channel
13.3.8. Japan
13.3.8.1. Market Revenue and Forecast, by Drug Class
13.3.8.2. Market Revenue and Forecast, by Treatment Type
13.3.8.3. Market Revenue and Forecast, by Type
13.3.8.4. Market Revenue and Forecast, by Route of Administration
13.3.8.5. Market Revenue and Forecast, by Distribution Channel
13.3.9. Rest of APAC
13.3.9.1. Market Revenue and Forecast, by Drug Class
13.3.9.2. Market Revenue and Forecast, by Treatment Type
13.3.9.3. Market Revenue and Forecast, by Type
13.3.9.4. Market Revenue and Forecast, by Route of Administration
13.3.9.5. Market Revenue and Forecast, by Distribution Channel
13.4. MEA
13.4.1. Market Revenue and Forecast, by Drug Class
13.4.2. Market Revenue and Forecast, by Treatment Type
13.4.3. Market Revenue and Forecast, by Type
13.4.4. Market Revenue and Forecast, by Route of Administration
13.4.5. Market Revenue and Forecast, by Distribution Channel
13.4.6. GCC
13.4.6.1. Market Revenue and Forecast, by Drug Class
13.4.6.2. Market Revenue and Forecast, by Treatment Type
13.4.6.3. Market Revenue and Forecast, by Type
13.4.6.4. Market Revenue and Forecast, by Route of Administration
13.4.6.5. Market Revenue and Forecast, by Distribution Channel
13.4.7. North Africa
13.4.7.1. Market Revenue and Forecast, by Drug Class
13.4.7.2. Market Revenue and Forecast, by Treatment Type
13.4.7.3. Market Revenue and Forecast, by Type
13.4.7.4. Market Revenue and Forecast, by Route of Administration
13.4.7.5. Market Revenue and Forecast, by Distribution Channel
13.4.8. South Africa
13.4.8.1. Market Revenue and Forecast, by Drug Class
13.4.8.2. Market Revenue and Forecast, by Treatment Type
13.4.8.3. Market Revenue and Forecast, by Type
13.4.8.4. Market Revenue and Forecast, by Route of Administration
13.4.8.5. Market Revenue and Forecast, by Distribution Channel
13.4.9. Rest of MEA
13.4.9.1. Market Revenue and Forecast, by Drug Class
13.4.9.2. Market Revenue and Forecast, by Treatment Type
13.4.9.3. Market Revenue and Forecast, by Type
13.4.9.4. Market Revenue and Forecast, by Route of Administration
13.4.9.5. Market Revenue and Forecast, by Distribution Channel
13.5. Latin America
13.5.1. Market Revenue and Forecast, by Drug Class
13.5.2. Market Revenue and Forecast, by Treatment Type
13.5.3. Market Revenue and Forecast, by Type
13.5.4. Market Revenue and Forecast, by Route of Administration
13.5.5. Market Revenue and Forecast, by Distribution Channel
13.5.6. Brazil
13.5.6.1. Market Revenue and Forecast, by Drug Class
13.5.6.2. Market Revenue and Forecast, by Treatment Type
13.5.6.3. Market Revenue and Forecast, by Type
13.5.6.4. Market Revenue and Forecast, by Route of Administration
13.5.6.5. Market Revenue and Forecast, by Distribution Channel
13.5.7. Rest of LATAM
13.5.7.1. Market Revenue and Forecast, by Drug Class
13.5.7.2. Market Revenue and Forecast, by Treatment Type
13.5.7.3. Market Revenue and Forecast, by Type
13.5.7.4. Market Revenue and Forecast, by Route of Administration
13.5.7.5. Market Revenue and Forecast, by Distribution Channel
14.1. Johnson & Johnson Services, Inc. (U.S.)
14.1.1. Company Overview
14.1.2. Product Offerings
14.1.3. Financial Performance
14.1.4. Recent Initiatives
14.2. Pfizer Inc. (U.S.)
14.2.1. Company Overview
14.2.2. Product Offerings
14.2.3. Financial Performance
14.2.4. Recent Initiatives
14.3. AbbVie Inc. (U.S.)
14.3.1. Company Overview
14.3.2. Product Offerings
14.3.3. Financial Performance
14.3.4. Recent Initiatives
14.4. Novartis AG (Switzerland)
14.4.1. Company Overview
14.4.2. Product Offerings
14.4.3. Financial Performance
14.4.4. Recent Initiatives
14.5. LEO Pharma A/S (Denmark)
14.5.1. Company Overview
14.5.2. Product Offerings
14.5.3. Financial Performance
14.5.4. Recent Initiatives
14.6. Merck & Co., Inc. (U.S.)
14.6.1. Company Overview
14.6.2. Product Offerings
14.6.3. Financial Performance
14.6.4. Recent Initiatives
14.7. UCB S.A. (Belgium)
14.7.1. Company Overview
14.7.2. Product Offerings
14.7.3. Financial Performance
14.7.4. Recent Initiatives
14.8. Sun Pharmaceutical Industries Ltd. (India)
14.8.1. Company Overview
14.8.2. Product Offerings
14.8.3. Financial Performance
14.8.4. Recent Initiatives
14.9. Amgen Inc. (U.S.)
14.9.1. Company Overview
14.9.2. Product Offerings
14.9.3. Financial Performance
14.9.4. Recent Initiatives
14.10. Eli Lilly and Company (U.S.)
14.10.1. Company Overview
14.10.2. Product Offerings
14.10.3. Financial Performance
14.10.4. Recent Initiatives
15.1. Primary Research
15.2. Secondary Research
15.3. Assumptions
16.1. About Us
16.2. Glossary of Terms
For questions or customization requests, please reach out to us at sales@precedenceresearch.com
No cookie-cutter, only authentic analysis – take the 1st step to become a Precedence Research client
